FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367721085> ?p ?o ?g. }

• W4367721085 abstract "<h3>Background and Importance</h3> Different JAK inhibitors (JAKi) are recently marketed at Spain for the treatment of rheumatoid arthritis (RA). However, there is little data about their persistence when a previous JAKi has been used on RA treatment, which could influence pharmacotheraphy with these drugs. <h3>Aim and Objectives</h3> To analyse the persistence to treatment with a second JAKi treatment in RA patients which have previously been treated with a first JAKi. <h3>Material and Methods</h3> Observational, retrospective study including all patients with RA treated with more than one JAKi until August 31, 2022. Demographic variables, median disease duration, median time on treatment (mToT) of JAKis including causes of end of treatment (loss of effectiveness or adverse reaction). Persistence was measured through mToT. <h3>Results</h3> 18 patients (16 women), median age of 48 years [interquartile range (IQR):40–55] were included. Median time from diagnosis 9.4 years (IQR:6.3–11.8). Concomitant treatment: methotrexate (n=7) or leflunomide (n=2). Before first JAKi treatment, 12 patients were treated previously with at least a biologic disease-modifying antirheumatic drug (bDMARD). 4 patients were treated with at least a bDMARD after finishing first JAKi, rest of patient switched directly to another second JAKi. Total mToT with the first JAKi: 12.1 months (IQR:3.3–31.3). Causes of end of treatment: loss of effectiveness (n=11; mToT: 15.7 months, IQR:11.9–35.3) and adverse effects (n=6; mToT: 2.5 months, IQR:1.4–4.7); a patient changed JAKi treatment due to cardiovascular risk. Among patients who finished first JAKi due to loss of effectiveness (n=11), mToT with second JAKi was 9.6 months (IQR:4.1 -14.2; 6/11 continue treatment; 1/11 loss of follow-up). Considering only patients who finished both first and second JAKi due to loss of effectiveness (n=4), mToT was 12.5 months (IQR: 8.0 -17.7) vs 6.6 (IQR:3.1–16.1) respectively. 33% of patients (2/6) who finished first JAKi treatment because of adverse effects did not tolerate neither the second JAKi (mToT: 2.5 months, IQR:1.4–140; 3/6 continue treatment). <h3>Conclusion and Relevance</h3> Persistence is higher with first JAKi when treatment with both first and second JAKi finished due to loss of efficacy, however data is still immature. Patients who do not tolerate treatment with a first JAKi seems to have a higher chance of not tolerating a second JAKi. <h3>References and/or Acknowledgements</h3> <h3>Conflict of Interest</h3> No conflict of interest" @default.
• W4367721085 created "2023-05-04" @default.
• W4367721085 creator A5043952761 @default.
• W4367721085 creator A5046095156 @default.
• W4367721085 creator A5072563018 @default.
• W4367721085 creator A5087113422 @default.
• W4367721085 date "2023-03-01" @default.
• W4367721085 modified "2023-09-26" @default.
• W4367721085 title "5PSQ-015 Persistence of treatment with jak inhibitors in rheumatoid arthritis in patients already treated with them" @default.
• W4367721085 doi "https://doi.org/10.1136/ejhpharm-2023-eahp.437" @default.
• W4367721085 hasPublicationYear "2023" @default.
• W4367721085 type Work @default.
• W4367721085 citedByCount "0" @default.
• W4367721085 crossrefType "proceedings-article" @default.
• W4367721085 hasAuthorship W4367721085A5043952761 @default.
• W4367721085 hasAuthorship W4367721085A5046095156 @default.
• W4367721085 hasAuthorship W4367721085A5072563018 @default.
• W4367721085 hasAuthorship W4367721085A5087113422 @default.
• W4367721085 hasBestOaLocation W43677210851 @default.
• W4367721085 hasConcept C126322002 @default.
• W4367721085 hasConcept C197934379 @default.
• W4367721085 hasConcept C2775905006 @default.
• W4367721085 hasConcept C2777575956 @default.
• W4367721085 hasConcept C2778715236 @default.
• W4367721085 hasConcept C2779384505 @default.
• W4367721085 hasConcept C71924100 @default.
• W4367721085 hasConceptScore W4367721085C126322002 @default.
• W4367721085 hasConceptScore W4367721085C197934379 @default.
• W4367721085 hasConceptScore W4367721085C2775905006 @default.
• W4367721085 hasConceptScore W4367721085C2777575956 @default.
• W4367721085 hasConceptScore W4367721085C2778715236 @default.
• W4367721085 hasConceptScore W4367721085C2779384505 @default.
• W4367721085 hasConceptScore W4367721085C71924100 @default.
• W4367721085 hasLocation W43677210851 @default.
• W4367721085 hasOpenAccess W4367721085 @default.
• W4367721085 hasPrimaryLocation W43677210851 @default.
• W4367721085 hasRelatedWork W1922756558 @default.
• W4367721085 hasRelatedWork W1971595431 @default.
• W4367721085 hasRelatedWork W2104455431 @default.
• W4367721085 hasRelatedWork W2292323398 @default.
• W4367721085 hasRelatedWork W2353831908 @default.
• W4367721085 hasRelatedWork W2372955595 @default.
• W4367721085 hasRelatedWork W2394123269 @default.
• W4367721085 hasRelatedWork W2396944180 @default.
• W4367721085 hasRelatedWork W2980569395 @default.
• W4367721085 hasRelatedWork W3025091143 @default.
• W4367721085 isParatext "false" @default.
• W4367721085 isRetracted "false" @default.
• W4367721085 workType "article" @default.